"Gemfibrozil" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
| Descriptor ID |
D015248
|
| MeSH Number(s) |
D02.241.081.114.968.500.750 D02.241.081.944.509.350 D02.355.726.305.750 D02.455.426.559.389.657.654.305.750 D10.251.400.895.593.350
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gemfibrozil".
Below are MeSH descriptors whose meaning is more specific than "Gemfibrozil".
This graph shows the total number of publications written about "Gemfibrozil" by people in this website by year, and whether "Gemfibrozil" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2002 | 1 | 0 | 1 |
| 2007 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2012 | 5 | 0 | 5 |
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 0 | 2 |
| 2019 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gemfibrozil" by people in Profiles.
-
Lipid-Lowering Drug Gemfibrozil Protects Mice from Tay-Sachs Disease via Peroxisome Proliferator-Activated Receptor a. Cells. 2023 Dec 08; 12(24).
-
Activation of PPARa Exhibits Therapeutic Efficacy in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis. J Neurosci. 2023 03 08; 43(10):1814-1829.
-
Gemfibrozil Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease via PPARa-Dependent Astrocytic GDNF Pathway. J Neurosci. 2021 03 10; 41(10):2287-2300.
-
Activation of Peroxisome Proliferator-Activated Receptor-a Increases the Expression of Nuclear Receptor Related 1 Protein (Nurr1) in Dopaminergic Neurons. Mol Neurobiol. 2019 Nov; 56(11):7872-7887.
-
Safety and potential efficacy of gemfibrozil as a supportive treatment for children with late infantile neuronal ceroid lipofuscinosis and other lipid storage disorders. Orphanet J Rare Dis. 2017 06 17; 12(1):113.
-
Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis. J Neurochem. 2017 05; 141(3):423-435.
-
Activation of peroxisome proliferator-activated receptor a induces lysosomal biogenesis in brain cells: implications for lysosomal storage disorders. J Biol Chem. 2015 Apr 17; 290(16):10309-24.
-
Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor a: implications for late infantile Batten disease therapy. J Biol Chem. 2012 Nov 09; 287(46):38922-35.
-
Gemfibrozil, a lipid-lowering drug, increases myelin genes in human oligodendrocytes via peroxisome proliferator-activated receptor-?. J Biol Chem. 2012 Oct 05; 287(41):34134-48.
-
Gemfibrozil, a lipid-lowering drug, upregulates IL-1 receptor antagonist in mouse cortical neurons: implications for neuronal self-defense. J Immunol. 2012 Jul 15; 189(2):1002-13.